The discovery of the downregulation of miR-26b in pulmonary artery remodeling, as well as its regulation of its target genes, CTGF and CCND1, may have important implications in our understanding of the molecular mechanisms underlying PAH, and may also lead to the development of new therapeutic interventions in this devastating and life-threatening disease. The gene discussed is CCND1; the disease is pulmonary arterial hypertension.